Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Invested Capital (2016 - 2025)

Bioadaptives' Invested Capital history spans 8 years, with the latest figure at -$391252.0 for Q4 2025.

  • On a quarterly basis, Invested Capital rose 4.73% to -$391252.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$391252.0, a 4.73% increase, with the full-year FY2025 number at -$391252.0, up 4.73% from a year prior.
  • Invested Capital hit -$391252.0 in Q4 2025 for Bioadaptives, up from -$497804.0 in the prior quarter.
  • Over the last five years, Invested Capital for BDPT hit a ceiling of -$370662.0 in Q2 2025 and a floor of -$804763.0 in Q3 2022.
  • Historically, Invested Capital has averaged -$599070.0 across 5 years, with a median of -$622375.0 in 2022.
  • Biggest five-year swings in Invested Capital: skyrocketed 64.37% in 2021 and later tumbled 77.66% in 2024.
  • Tracing BDPT's Invested Capital over 5 years: stood at -$535997.0 in 2021, then crashed by 42.66% to -$764645.0 in 2022, then rose by 12.54% to -$668759.0 in 2023, then skyrocketed by 38.59% to -$410669.0 in 2024, then rose by 4.73% to -$391252.0 in 2025.
  • Business Quant data shows Invested Capital for BDPT at -$391252.0 in Q4 2025, -$497804.0 in Q3 2025, and -$370662.0 in Q2 2025.